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Abstract
Nanoparticle-based contrast agents are attracting a great deal of attention for various biomedical
imaging and theranostic applications. Compared to conventional contrast agents, nanoparticles
possess several potential advantages to improve in vivo detection and to enhance targeting
efficiency. Silica-based nanoprobes can be engineered to achieve longer blood circulation times,
specific clearance pathways, and multivalent binding. In this tutorial review, we summarize the
latest progress on designing silica-based nanoprobes for imaging and theranostic applications. The
synthesis of both solid silica and mesoporous silica nanoparticles is described, along with different
approaches used for surface functionalization. Special emphasis is placed on the application of
silica-based nanoprobes in optical, magnetic resonance, and multimodal imaging. The latest
breakthroughs in the applications of silica nanoparticles as theranostic agents are also highlighted.
Introduction
Nanomaterials have recently become one of the most active research fields in the areas of
engineering, chemistry, solid state physics, biotechnology, and biomedicine. One reason for
this interest is that nanomaterials display novel, and often enhanced, properties compared to
traditional materials, which opens up the potential for new technological applications. In
particular, imaging technologies benefit greatly from using nanomaterials as contrast
enhancement agents and molecular probes.1,2 For example, semiconducting quantum dot
(QD) nanoparticles have been a popular option for fluorescent optical imaging due to their
broad absorption spectra, narrow and tunable emission spectra, photostability, and high
efficiency.3 Colloidal gold nanoparticles exhibit unique optical and electrical properties (e.g.
surface plasmon resonance), and can be readily functionalized with biological molecules.4
As a result, gold nanoparticles have been evaluated for biosensing and as contrast agents for
computed tomography (CT). Gold nanoparticles are also being explored for photoacoustic
computed tomography (PAT) applications. Superparamagnetic iron oxide nanoparticles
(SPIONs) have been used as contrast agents for magnetic resonance imaging (MRI), drug
delivery systems, and biosensors.5 Recently, nanoscale metal–organic frameworks
(NMOFs), also known as nanoscale coordination polymers, have been tested for a wide
variety of biomedical applications.6 NMOFs possess many desirable features such as high
agent loading, intrinsic biodegradability as a result of labile metal–ligand bonds, high
porosity, and versatile functionalization methodologies. NMOFs have been evaluated as
novel MRI contrast agents due to their ability to carry large amounts of paramagnetic metal
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centers and their high per-metal-based relaxivities.7 They have also been explored for other
imaging modalities, such as CT and optical imaging (OI).8,9
Interestingly, in contrast to many other nanomaterials, silica nanoparticles do not acquire
any special property from their sub-micrometre size, except for the corresponding increase
in surface area. What makes silica nanoparticles fascinating from a nanotechnology point of
view is their well-defined and tunable structures (i.e. size, morphology, and porosity) and
surface chemistry. By introducing new functional groups via well-established siloxane
chemistry, we can modify the silica surface to impart new properties to the particles, such as
diagnostic and therapeutic capabilities.10 Silica nanoparticles are effectively “transparent” in
the sense that they do not absorb light in the near-infrared (NIR), visible, and ultraviolet
regions or interfere with magnetic fields. In addition, silica nanoparticles are inexpensive,
easy to prepare, relatively chemically inert, biocompatible, and water dispersible. This
article reviews recent advances in the development of silica nanoparticles as contrast agents
for biomedical imaging and theranostic applications.
Synthesis and functionalization of silica nanoparticles
There are two major types of silica-based nanoparticles: solid silica nanoparticles (SiNPs)
and mesoporous silica nanoparticles (MSNs). Functionalized SiNPs have been extensively
utilized as optical imaging contrast agents and as drug delivery vehicles. As optical contrast
agents, SiNPs possess attractive features such as photophysical stability, biocompatibility,
and favorable colloidal properties. In addition, the silica surface can be modified by various
functional groups such as antibodies, aptamers, and polymers.11 Typically, two common
approaches, the Stöber method and reverse microemulsions, are used to synthesize SiNPs.
These methods are based on a sol–gel process in which the hydrolysis of a silicon alkoxide
precursor is carried out, followed by the polycondensation of the monomers to afford the
desired nanoparticles.
On the other hand, MSNs exhibit many unique properties such as high surface areas, stable
and rigid frameworks, tunable pore sizes, and large pore volumes. MSNs are typically
synthesized by a surfactant-templated sol–gel approach.12 MSNs of the MCM-41 structures
(MCM stand for Mobil Composition of Matter), for example, possess a honeycomb-like, 2D
hexagonal porous structure with empty channels that are able to encapsulate relatively high
amounts of functional molecules and shelter them from exposure to the external
environment. In addition, these materials have two different surfaces, the interior channel
surface and the exterior particle surface, which offer many advantages over solid particles.
Some of the strategies for the synthesis and functionalization of SiNPs and MSNs are
described in the following section. More specialized reviews focusing on the synthesis and
functionalization of SiNPs13 and MSNs14 have recently been published.
Solid silica nanoparticles
The Stöber method and the reverse microemulsion method are generally used to synthesize
SiNPs (Fig. 1). The Stöber method, also known as the sol–gel method, was developed by
Stöber and coworkers in the late 1960s.15 The synthesis involves the controlled hydrolysis
and condensation of a silica precursor, such as tetraethoxysilane (TEOS), in ethanol and
water with ammonia as a catalyst. The size of the particles can be tuned by adjusting the
reaction conditions. The nanoparticles obtained by this method are typically monodisperse
and spherical in shape. SiNPs remain dispersible in solution due to electrostatic repulsion
from their negative surface charges. The Stöber method can also be used to synthesize core–
shell nanoparticles when a pre-synthesized core is suspended in the solution.16
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The reverse microemulsion method was developed by Arriagada and Osseo-Asare in the
early 1990s.17 This approach involves the ammonia-catalyzed polymerization of TEOS in a
reverse phase, or water-in-oil, microemulsion. Reverse microemulsions are highly tunable
systems that consist of nanometre-sized water droplets stabilized by a surfactant in the
organic phase. The micelles of the microemulsion act as “nanoreactors” in which particle
growth occurs and the final size is controlled by the water to organic solvent ratio. With this
method, highly monodisperse and perfectly spherical particles are obtained with sizes
ranging from 20 to 100 nm. The reverse microemulsion method is ideal for producing
monodisperse silica nanoparticles smaller than 100 nm.
SiNPs can be functionalized by the addition of hydrophilic functional molecules, which
allows for incorporation of organic species within the silica matrix. In this case, functional
molecules are entrapped in the silica framework via noncovalent interactions. For example,
fluorophores such as the tris(2,2′-bipyridyl)dichlororuthenium(II) complex (Ru(bpy3))2+ can
be doped into the nanoparticles during the synthesis to impart luminescent properties.18
Interestingly, entrapped luminophores exhibit a higher quantum yield and enhanced
photostability than the free dye molecules. The entrapped dye molecules can leach from the
nanoparticles under certain conditions. Functional molecules can also be integrated within
the matrix by using organoalkoxysilane derivatives.11 In this way, small molecules are
chemically incorporated within the nanoparticle via siloxane linkages, leading to stable
hybrid silica nanoparticles with uniform functionalization throughout the nanoparticle and
protected from the environment. Entrapped molecules also ameliorate their detrimental
intrinsic properties. For example, the release rate of drug molecules can be controlled once
loaded inside the silica matrix, and toxicities of QDs and metal nanoparticles are suppressed
under the protection of silica shells. Surface functionalization can be achieved by reacting
preformed silica nanoparticles with trialkoxysilane derivatives after the nanoparticle
synthesis. Post-synthetic grafting is particularly useful for modifying the particle surface
with selected agents that are not stable during the silica particle synthesis. In addition, the
ability to synthesize nanoparticles with core–shell architectures allows multiple functions to
be incorporated within a single platform. For example, gold, QDs, and SPIONs have been
embedded into silica nanoparticles to impart catalytic, imaging, and biological
capabilities.19
Mesoporous silica nanoparticles
Several adjustments to the traditional Stöber method have been reported for the preparation
of silica nanoparticles. For example, mesoporous silica particles (MSNs) were prepared by
modifying the conditions of the original sol–gel method in the presence of high
concentrations of surfactant molecules. The synthesis of MSNs occurs by the formation of
liquid-crystalline mesophases of amphiphilic surfactants that function as templates for the
polymerization of silica precursors (Fig. 2). The synthesis can be carried out in either acidic
or basic conditions. The first reported material, MCM-41, was micrometre-sized particles
without a well-defined shape containing hexagonally-ordered channels. Recently, several
methods have been developed to control the morphology, pore size, and surface
functionalization of MSNs.12,20 These methodologies have afforded MSNs with different
morphologies such as spheres, rods, twisted columns, and kidney bean-shaped nanoparticles.
MSNs with particle diameters ranging from 60 to 1000 nm have been synthesized using
these methods.
MSNs can be chemically functionalized by two approaches: post-synthetic grafting or co-
condensation (Fig. 3). Post-synthetic grafting is the most popular approach for covalently
incorporating organic functionalities onto the mesoporous material. This method is based on
a condensation reaction between a given trialkoxysilane and the free silanol and geminal
silanol groups on the silica surface. This method allows the particle morphology and pore
Vivero-Escoto et al. Page 3













structure to remain intact, but it has been found that most materials functionalized using this
grafting method contain an inhomogeneous coverage of organic functional groups. Using
this approach, stimuli-responsive capped MSNs have been synthesized for drug delivery.21
Alternatively, MSNs can be functionalized via the co-condensation method. In this
approach, the desired trialkoxysilane is condensed into the pores of MSNs during the
nanoparticle synthesis, leading to homogeneous incorporation of the functional group
throughout the material.12 The selection of the trialkoxysilane precursor is limited to those
with organic functional groups that would be soluble in water and can tolerate the extreme
pH conditions that are required for the synthesis of MSNs and subsequent removal of
surfactants. The degree of functionalization, particle size, and morphology can be modified
by adjusting the synthetic conditions, such as reagent concentration and the hydrophobicity/
hydrophilicity of the trialkoxysilane reagents. The combination of both synthetic approaches
has afforded multifunctional platforms with a wide variety of applications in biotechnology
and biomedicine.20,21
Biomedical imaging applications of silica nanoparticles
Noninvasive imaging techniques are valuable tools in the arsenal of clinical diagnostics. A
diverse range of imaging modalities is now available, from techniques that enable whole-
organism anatomical imaging such as MRI and CT, to others that provide specific molecular
imaging such as positron electron tomography (PET) and optical fluorescence. Several
nanoparticle-based contrast agents have been developed to overcome issues that plague
conventional contrast agents. Some of the most important prerequisites for designing
nanoparticle-based contrast agents are outlined below:
• Form stable colloidal solutions in a wide variety of in vitro and in vivo
environments
• Possess chemical stability under a wide variety of physiological conditions (i.e.
solvent polarity, reducing environment, ionic strength, pH, or temperature)
• Exhibit limited nonspecific binding to avoid macrophagocytic system (MPS)
uptake
• Have programmed clearance mechanisms
• Display high sensitivity and selectivity for the target (i.e., antigen, cell, or tissue)
• Show good image contrast (high signal-to-noise ratio)
• Have sufficiently long circulation time in the blood if administered intravenously
Ideally, these nanomaterials will be suitable for long-term quantitative imaging at low doses
and be safely cleared from the body after imaging is complete. Nanoparticulate silica-based
contrast agents are a promising platform to meet the aforementioned requirements.
Silica-based imaging nanoprobes are most commonly used for OI, MRI, or a combination of
both modalities. OI is a low cost technology and allows for rapid screening, whereas MRI
can offer high resolution and the capacity to simultaneously obtain physiological and
anatomical information.
OI is a powerful modality in which specific probes are excited by incident light, usually in
the visible or NIR regions, and emit light at a lower energy than the incident light. As
radiation is scattered and absorbed quickly within the body, the resolution for OI is limited
to 1–2 mm. The need for deeper penetration depths for most clinical applications is driving
optical techniques into the NIR region (650–950 nm). OI is a versatile imaging technique in
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terms of availability of a variety of contrast agents, avoidance of radiopharmaceuticals, and
relatively low cost of instrumentation. These features make OI complementary to other
modalities such as MRI and PET.
MRI is currently one of the most powerful in vivo imaging technologies, with the advantage
of being a noninvasive diagnostic tool that provides high resolution three-dimensional
anatomical images of soft tissue. MRI exploits the remarkable range of the physical and
chemical properties of water protons.22,23 The signal detected in MRI results from a
combination of total water signal (proton density) and the magnetic properties of the tissues.
The magnetic properties in question are the longitudinal relaxation time, T1, and the
transverse relaxation time, T2. The reciprocals of these values represent the longitudinal and
transverse relaxivities, r1 and r2, respectively. T1 and T2 times are dependent upon the
physicochemical environment of a given tissue and are modified in the presence of a
pathological state. Contrast enhancement agents are used in imaging to increase the signal
difference between the area of interest and the background. In MRI, the sensitivity and
exceptional soft tissue contrast are further improved by the use of MR contrast agents that
alter the local MR signal intensity. There are two main classes of contrast agents for MRI:
paramagnetic complexes and superparamagnetic iron oxide particles. The former class
includes mainly chelates of Mn(II), Mn(III), and Gd(III) ions, with Gd-based agents being
the most common. The Gd contrast agents currently available lack sensitivity and, thus, high
concentrations of contrast agent are required. The use of a nanoparticle platform provides
several advantages over small molecule contrast agents. For example, a high payload of a
molecular contrast agent can be incorporated within a single nanoparticle, thus increasing
the effective relaxivity per nanoparticle. The increased size results in reduced tumbling
rates, which increases the relaxivity on a per metal basis.
Solid silica nanoparticles
Many studies incorporating dye molecules into SiNPs for OI have been published. Dye-
doped SiNPs were first synthesized by Van Blaaderen and coworkers using the Stöber
method with the conjugation of fluorescein isothiocyanate (FITC) with (3-
aminopropyl)trimethoxysilane.24 However, the particles obtained by this method were
polydisperse and large (particle diameter of >400 nm). Santra and coworkers synthesized
FITC-doped SiNPs in reverse microemulsions,25 which were further modified with the TAT
peptide, a cell-penetrating peptide. To demonstrate biolabeling efficiency, the authors
labeled A549 human non-small cell lung cancer and SCC-9 human squamous
adenocarcinoma cells in vitro. The in vivo bioimaging capability of this platform was
demonstrated by selectively labelling brain blood vessels via intra-arterial administration
through the right common carotid artery of a rat. The authors showed that by using TAT-
coated SiNPs, it is possible to deliver diagnostic agents to the brain without compromising
the blood brain barrier (BBB).
Luminescent metal complexes such as Ru(bpy)32+ have also been incorporated into SiNPs
for OI. The large Stokes shift of this complex significantly reduces the background signal
from biological systems. Additionally, Ru(bpy)32+ is much more photostable than organic
fluorophores such as fluorescein. In 2001, Tan and coworkers reported the synthesis of
Ru(bpy)32+-doped SiNPs by the reverse microemulsion method, yielding monodisperse,
spherical nanoparticles 63 nm in diameter.26 This platform exhibited several advantages
over small-molecule dyes, such as enhanced signals, increased photostability, homogenous
fluorophore distribution, and protection from the external environment. These particles were
used as biomarkers by conjugation with an antibody specific for leukemia cells. The
leukemia cells were identified easily, concisely, and with high efficiency using the antibody-
coated SiNPs. The authors further optimized the reverse microemulsion synthesis of the
Ru(bpy)32+-doped SiNP platform. By changing parameters such as TEOS and ammonium
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hydroxide concentrations, type of surfactant, and the molar ratios of water to surfactant and
cosurfactant to surfactant, the authors were able to investigate the effects on the fluorescence
spectra, particle size, and size distribution of Ru(bpy)32+-doped SiNPs.18 Tan and coworkers
recently reported findings on the in vivo behavior of these nanoparticles.27 The authors
investigated the biodistribution and urinary excretion of three types of surface-modified
Ru(bpy)32+-doped SiNPs (OH–SiNPs, COOH–SiNPs, and PEG–SiNPs) via an OI method
(PEG = poly(ethylene glycol). PEG is widely used to enhance the biocompatibility and
blood circulation time by preventing the nonspecific adsorption of proteins. Results for these
in vivo imaging studies showed that PEGylated Ru(bpy)32+-doped SiNPs exhibited longer
blood circulation times (t1/2 = 180 ± 40 min) and minimal MPS organ uptake than OH–
SiNPs and COOH–SiNPs (Fig. 4). Interestingly, in vivo real-time imaging showed that all
three types of intravenously-injected SiNPs with a size of approximately 45 nm were
partially excreted through the renal excretion route; ex vivo analysis of organs and urine
confirmed these results.
Wiesner and coworkers synthesized highly fluorescent SiNPs by a modified Stöber
method.28 The organic dye (tetramethylrhodamine isothiocyanate, TRITC) was first
covalently conjugated to a silica precursor to form a dye-rich core, and silica monomers
were subsequently added to afford the core–shell fluorescent SiNPs, referred to as Cornell
dots (C dots). These 20–30 nm particles were ~20 times brighter than the constituent dye.
The bioimaging utility of these nanoparticles was demonstrated by labelling rat basophilic
leukemia mast cells. A thorough investigation of the toxicity and biodistribution of C dots
was carried out by Nikitin, Wiesner, and coworkers.29 No apparent toxicity in the mice was
observed. Multiphoton microscopy was used to demonstrate the capability of C dots in
sentinel lymph node mapping. C dots can be surface-modified to expand their scope of
application. For instance, Langer and coworkers electrostatically coated C dots with cationic
polymers to change their surface charge, enabling the particles to escape from the
endosomes and enter the cytoplasm and nucleus. Using this strategy, the cellular uptake
increased; and these nanoparticles were used as DNA delivery carriers.30
The synthesis of C dots was further modified to allow the incorporation of NIR dyes, surface
functionalization to avoid opsonization, and multimodal imaging capabilities. Wiesner,
Bradbury, and coworkers recently reported the synthesis of NIR C dots with hydrodynamic
diameters of 3.3 and 6.0 nm.31 These nanoparticles contained the NIR dye molecule Cy5
(λem > 650 nm) and displayed improved photophysical characteristics compared to the
parent dye. Biodistribution studies in mice showed that these nanoparticles are partially
excreted through the renal pathway; however, significant accumulation in the liver was
observed. Further surface modification with PEG (0.5 kDa) showed increased renal
excretion and decreased liver uptake compared to the unmodified particles (Fig. 5). The
larger 6.0 nm particles exhibited a longer blood circulation time, longer urine half-life, and
greater organ retention. Recently, Bradbury and coworkers further modified C dots to afford
the next generation of these nanoparticles. This material was designed considering the
following features: tumor selectivity, nontoxicity, enhanced targeting, and favorable
clearance profiles.32 These 7 nm particles were synthesized as described above and further
functionalized with the cyclic RGD peptide, a target for the αvβ3 integrin which is
overexpressed in a number of malignant endothelial cell lines, and labeled with the radio-
nuclide 124I. These modified C dots exhibited high-affinity binding in vitro, favorable
tumor-to-blood residence time ratios, and enhanced tumor-selective accumulation in αvβ3
integrin-expressing melanoma xenografts in mice (Fig. 6). In addition, this platform showed
high sensitivity, real-time detection and imaging of lymphatic drainage patterns, favorable
particle clearance rates, and differential tumor burden in a large animal model (miniswine).
This multimodal optical-PET imaging system has recently received FDA approval for a
first-in-human clinical trial as a cancer-specific optical probe.32
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Other approaches have also been explored to develop silica-based OI contrast agents for
biomedical applications. Prasad and coworkers reported on the use of multimodal
organically-modified silica (ORMOSIL) nanoparticles for in vivo bioimaging.33 These 20–
25 nm particles, synthesized using a modified Stöber method, contained a near-IR
fluorophore molecule (DY776), and a radio-nuclei 124I label for optical and PET imaging in
vivo. The authors studied the biodistribution, clearance, and toxicity of these multimodal
nanoparticles. The biodistribution of non-targeted nanoparticles was studied in nontumored
mice by optical and PET imaging. These studies showed a greater accumulation of
nanoparticles in the liver, spleen, and stomach than in the kidneys, heart, and lungs. The
clearance studies carried out over a period of 15 days indicated hepatobiliary excretion of
the nanoparticles. No apparent toxicity in the mice was observed.
The use of the two-photon absorption approach to overcome the issue of poor depth
penetration in OI has attracted a great deal of attention in recent years. Belfield and
coworkers synthesized SiNPs containing a two-photon absorbing and aggregation-enhanced
NIR-emitting pyran derivative.34 These particles were surface-modified with PEG and folic
acid (FA) to endow targeting capabilities to the nanoprobe. In addition, this platform can be
used for two-photon fluorescence microscopy, a well-known technique which provides
three-dimensional (3D) cellular-level resolution. These particles were 20–30 nm in size and
exhibited a 3-fold increase in two-photon absorption and improved stability over the
constituent dye. No apparent toxicity was observed either in vitro or in vivo. The efficient
targeting ability of these SiNPs was demonstrated by intravenous injection into mice bearing
HeLa tumors. The nanoprobe not only targeted the tumor, but also penetrated deeply into the
tumor parenchyma, as demonstrated by ex vivo cellular-level two-photon fluorescence
microscopy imaging of the tumor.
The Lin group has focused on the development of multimodal imaging probes combining
the MRI and OI modalities. The synthesized 37 nm SiNPs contain an embedded Ru(bpy)32+
fluorophore and a shell of Gd–DTPA (DTPA = diethylene-triaminepentaacetate) chelates.35
The surface-immobilized Gd chelates possess relaxivities four orders of magnitude higher
than the parent Gd complex, presumably due to Gd chelates attached to the nanoparticles
efficiently relaxing water protons through a reduction in the tumbling rates. The Gd chelates
were also immobilized on the surface of SiNPs in a multilayer fashion by using a
bis(trialkoxysilyl) derivative of Gd–DTPA. However, the SiNPs prepared by this approach
exhibited reduced relaxivities on a per Gd basis compared with the monolayer system, likely
caused by reduced water accessibility of the Gd chelates.
The efficiency of these SiNPs as a multimodal in vitro imaging agent was tested using
murine monocyte cells. The monocytes were efficiently labelled, as indicated by flow
cytometry results and phantom MR image studies using a 3 T scanner (Fig. 7). This platform
can be used for target-specific MR imaging of inflammation by selective trafficking of
labelled monocyte cells, as demonstrated by OI and MR imaging using a collagen-induced
arthritis (CIA) mouse model.36 DBA-1J mice were immunized for CIA and imaged after the
disease onset. Optical images of the paws were obtained using an optical scanner with filters
specific for the spectrum of the Ru(bpy)32+ fluorophore (excitation: 445–490 nm, emission:
575–650 nm) (Fig. 8). The luminescence intensity correlated well with the clinical disease
index and paw swelling in animals that received the SiNP contrast agent, and the strength of
this correlation was dose dependent. The post-contrast MR images displayed a 33–55% T2
reduction when compared to the precontrast images (Fig. 9), corroborating the OI results.
Additionally, histopathologic tissue sections of arthritic paws were evaluated with light and
fluorescent microscopy to visualize the SiNPs within the hindlimbs. This analysis
demonstrated that the particles were located within the synovial tissue where the disease was
prevalent.
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The Lin group has also developed a polyelectrolyte layer-by-layer (LbL) self-assembly
approach for the synthesis of cancer-specific SiNPs with multimodal imaging capabilities.37
The platform was based on SiNPs containing a Ru(bpy)32+ core and a monolayer of a
negatively-charged Gd–DTPA derivative. This highly anionic nanoparticle was coated with
positively-charged Gd chelate oligomers. The resulting positively-charged particle was
further treated with negatively-charged polystyrenesulfonate to provide a net negatively-
charged layer. These steps were repeated to form the LbL multilayer architecture (Fig. 10).
The formation of the LbL SiNPs was confirmed by TEM and fluorescence studies. MR
measurements with a 3 T scanner showed that nanoparticles containing the positively-
charged Gd chelate (Gd-DOTA) had higher relaxivities on a per Gd basis than the
constituent paramagnetic center. Additionally, the LbL self-assembly increases the Gd
payload, thus, higher relaxivities on a per particle basis were obtained. To endow targeting
abilities to this platform, the K7RGD targeting group was absorbed on the negatively-
charged particles via electrostatic interactions. In vitro optical and MR imaging studies
demonstrated efficient targeting to HT-29 human colon adenocarcinoma cells by the LbL
SiNPs with the noncovalently-attached K7RGD peptide (Fig. 11).
Core–shell nanostructures have been used to incorporate Gd chelates onto QDs, SPIONs, or
gold nanoparticles.38,39 The cores of these nanoparticles provided optical and T2-weighted
contrast, whereas Gd chelates on the surface rendered T1-weighted MRI enhancements. The
biodistribution and blood circulation of these nanoparticles were studied. By functionalizing
the surface of NMOF@silica particles with lanthanide chelates, luminescent spore detectors
have been developed.40 In addition, NMOFs with silica shells have been explored for
optical, MR imaging, and biosensing applications.9,41,42
Mesoporous silica nanoparticles
Dye molecules have been incorporated into the silica framework of MSNs as a tool for
investigating cellular internalization and cell tracking.21 For example, Lindén and coworkers
synthesized MSNs for the delivery of imaging agents to cancer cells.43 The MSN material
was first surface-functionalized with poly(ethylene imine). The nanoparticles were then
labelled with FITC and modified with FA to endow the targeting ability. In vitro
experiments using HeLa cells showed that the folate-targeted particles were internalized in a
higher amount (5-fold) than the nontargeted nanoparticles. As mentioned previously, OI
usually suffers from the attenuation of photon propagation in living tissue and poor signal to
noise ratio due to tissue autofluorescence. To overcome these issues, Lo and coworkers
developed NIR MSN-based probes.44 Indocyanine green (ICG) was entrapped into MSNs
by electrostatic interactions. ICG is advantageous as a fluorophore for in vivo imaging as the
dye molecule has been approved by the FDA as an optical contrast agent for clinical
applications and its characteristic fluorescent excitation and emission wavelengths (λex/λem
= 800/820 nm) are in the NIR window. The authors demonstrated some of the benefits of
using MSNs as scaffolds for incorporating optical agents. For example, the homogeneous
dispersion of ICG molecules in the large surface area of MSNs efficiently prevents their
aggregation and self-quenching. Moreover, MSNs protect ICG molecules from degradation
and diminish the associated immune response. The authors evaluated the biodistribution of
this optical probe in rat and mouse models. Optical images revealed that after intravenous
injection, the nanoparticles immediately accumulated in liver, followed by the kidneys,
lungs, spleen, and heart (Fig. 12). Recently, Lo and coworkers studied the influence of
surface charge on the biodistribution of ICG–MSNs.45 The results showed that by
judiciously tailoring the surface charge of MSNs, it is possible to control both
biodistribution and the rate of excretion.
The Lin group demonstrated the use of MSNs as nanoparticulate T1-weighted MR contrast
agents in vitro and in vivo.46 The nanoprobe was synthesized via post-synthetic grafting of a
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silane derivative, Gd-Si-DTTA, by refluxing the material in toluene. The MR properties
were characterized by 3 T and 9.4 T MR scanners; the nanoparticles exhibited very large r1
and r2 relaxivities. The material was labelled with the fluorophore rhodamine B in order to
study the in vitro properties using an immortalized murine monocyte cell line. Both confocal
microscopy and in vitro phantom images showed that the nanoparticles were internalized by
the monocytes.
The MSN material was intravenously injected to a mouse to study the in vivo MR contrast
enhancement properties. T1-weighted contrast enhancement was clearly visible in the aorta
of the mouse 15 min post-injection. This enhancement shows the potential of the Gd–MSN
platform as an intravascular MR contrast agent (Fig. 13). Moreover, it was also
demonstrated that when administered in higher doses, this nanoprobe can be used as a T2-
weighted contrast agent. Signal loss was observed in the liver several days after
administration of the Gd–MSN material. The slow excretion of the Gd–MSN nanoprobe
after the MRI study, as well as consequent long-term tissue accumulation of toxic Gd3+ ions,
could result in potential toxicological issues. Recently, the Lin group synthesized a
multifunctional MSN-based MRI contrast agent that can be quickly excreted by the renal
pathway after imaging.47 This nanoprobe contains a Gd-chelate unit that is covalently bound
to MSN via a redox-responsive linker. The MSN-based MR imaging platform was further
functionalized with PEG and an anisamide ligand to improve its biocompatibility and target
specificity. Anisamide is known to target sigma receptors, which are overexpressed in a
number of epithelial cancer cell types. The effectiveness of this nanoprobe and its targeting
ability were successfully demonstrated in vitro using human colon adenocarcinoma and
pancreatic cancer cells. Finally, the biodegradability and capability of this platform as an in
vivo MR contrast agent was evaluated using a 3 T scanner. The Gd chelate unit was quickly
cleaved by the blood pool thiols and the Gd complex was rapidly eliminated via the renal
excretion pathway.
The ability to monitor cell trafficking and biodistribution in vivo is a prerequisite for
developing successful stem cell therapies. MR is an ideal noninvasive imaging technique for
tracking stem cells; however, cells must be magnetically labelled by endocytic
internalization. Hence, more efficient noninvasive cellular-internalizing platforms are highly
desirable. Huang, Mou, and coworkers have used silica nanoparticles as multimodal contrast
agents for tracking stem cells.48,49 The MSN-based dual-modal platform combines a
fluorescent dye (FITC) and a MR contrast agent. Both T2- and T1-weighted MR contrast
agents have been incorporated into this system. Small particles of iron oxide behave as
negative contrast agents to afford Mag-Dye@MSNs,49 and Gd-based chelates were grafted
onto MSNs to afford Gd-Dye@MSNs.48 Both systems were efficiently internalized into
human mesenchymal stem cells (hMSCs) without affecting cell viability, growth, or
differentiation. The efficient hMSCs tracking was visualized in vitro and in vivo by a
clinical 1.5 T MRI system. In vivo, the labeled cells remained detectable by MRI after long-
term growth or differentiation, providing further evidence of the biocompatibility and
durability of both of the Mag-Dye and Gd-Dye@MSNs nanoprobes (Fig. 14). In addition,
Mou and coworkers used the dual-modality Mag-Dye@MSNs system to follow the
biodistribution of MSNs in vivo after eye vein injection in a mouse model.49 T2-weighted
MR images revealed that the MSNs started to accumulate immediately in the liver, spleen,
and kidneys predominantly through a vascular mechanism, and signal darkening was
observed mainly in the liver and spleen due to nanoparticle accumulation within the RES at
later time points post injection. To confirm these results, histology slides prepared from the
above-mentioned organs of mice sacrificed 30 min after administration of Mag-Dye@MSNs
were visualized by a fluorescence microscope. Fluorescence due to FITC was observed in
the liver and spleen, but not in the kidneys. A long-term MRI tracking study in the liver
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showed that the Mag-Dye@MSNs are highly resistant to decomposition and not easily
excreted from the body.
Simultaneous imaging and therapeutic applications of silica nanoparticles
In recent years, there has been a remarkable level of research interest in using
multifunctional nanomaterials for simultaneous imaging and therapy. The field has
expanded so rapidly that the term “theranostic” (syn: theragnostic) has been coined to
describe platforms that serve dual roles as diagnostic and therapeutic agents.50 The
inspiration for this approach is that theranostic agents could provide the ability to
simultaneously monitor the disease, the therapeutic agent uptake, and the efficacy of the
treatment. One of the advantages of nanomaterials is that many of them are already imaging
agents (QDs, SPIONs, C dots, and Au nanoparticles) and can be readily “upgraded” to
theranostic agents by incorporating therapeutic functions on these platforms. In addition, an
underlying driving force of such a combination is that imaging and therapy both require
sufficient accumulation of agents in diseased areas. Silica nanoparticles are an excellent
scaffold for facile loading of a wide variety of imaging and therapeutic moieties, making
them promising candidates for theranostic applications. This section describes some of the
most illustrative examples of silica-based theranostic nanoparticles.
Solid silica nanoparticles
SiNPs have been recently used for photodynamic therapy (PDT) applications. PDT is a
localized treatment that destroys targeted cells with reactive oxygen species (ROS), such as
single oxygen (1O2), that are generated by irradiating a photosensitizer in the presence of
oxygen. PDT is particularly attractive because it combines two essentially harmless
elements (a photosensitizer and light) to produce singlet oxygen, which is known to be
destructive to cancer cells.51 In addition, the function of photosensitizers is not restricted
solely to the therapeutic generation of singlet oxygen. Many photosensitizers function as
bright fluorophores, and some of them emit in the NIR region of the spectra, which is
preferred for in vivo OI. Nanoparticle carrying photosensitizers can be used as theranostic
agents for PDT. Prasad and coworkers described the use of the ORMOSIL material for
PDT.52 The authors incorporated 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH),
a hydrophobic photosensitizer, into silica matrices. It was demonstrated that HPPH is more
fluorescent in the silica matrices than in the free form and can efficiently kill cancer cells
when irradiated with a laser. The main drawback of PDT is that currently approved
photosensitizers absorb in the visible spectral region, where light penetration depth is only a
few millimetres. This problem can be alleviated by using NIR dyes or combining a two-
photon absorbing dye with the photosensitizer. Hai and coworkers reported on the
preparation of 105 nm silica particles with entrapped methylene blue for OI and PDT.53 The
therapeutic efficacy of this system was demonstrated in vitro and in vivo.
Both fluorescence imaging and PDT were observed in a mouse xenograft model. After
intratumoral injection of the methylene blue-loaded nanoparticles, optical images of the
mice showed that the tumor region was clearly defined, and after laser treatment, the tumor
became necrotic (Fig. 15). Recently, Prasad and coworkers described the co-encapsulation
of HPPH and a two-photon absorbing dye, 9,10-bis[4′-(4″-aminostyryl)styryl]anthracene
(BDSA), into silica nanoparticles.54 It was shown that BDSA can efficiently up-convert the
NIR light and partially transfer the energy to HPPH to activate PDT function. NMOF@silica
particles have also been developed for theranostic applications; iron-carboxylate MIL-101
particles were post-synthetically modified to introduce both therapeutic and imaging
moieties.55
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MSNs are especially appropriate for the development of theranostic nanoparticles. Due to
their unique topology with three different domains—silica matrix, internal, and external
surfaces—MSNs can incorporate numerous functional groups, such as contrast agents,
therapeutics, and biomolecular targeting ligands. For example, Lo and coworkers developed
a MSN-based theranostic platform that was functionalized with three different chemical
entities. A NIR dye (ATTO 647N) was co-condensed into the silica framework, and a
photosensitizer (meso-tetratolylporphyrin-Pd, PdTPP) was grafted within the channels of
MSN. Finally, the exterior surface was functionalized with cyclic RGD attached to a PEG
chain.56 The authors evaluated the targeting specificity and uptake of nano-particles by
comparing tumor cells that lack the αvβ3 integrin (MCF-7 breast cancer) and those that
overexpress the αvβ3 integrin (U87-MG glioblastoma). The flow cytometry and confocal
microscopy data showed that U87-MG cells selectively internalize RGD-PdTPP-MSN
particles. PDT efficacy was tested by bioavailability assays under irradiation (532 nm diode
laser; 250 ± 5 mW cm−2) and non-irradiation conditions. The results revealed a dramatic
difference in post-irradiation cytotoxic response of U87-MG cells that have been treated
with RGD-PdTPP-MSN particles.
Brinker and coworkers have developed MSN-supported lipid bilayers (protocells) as a
theranostic platform (Fig. 16).57 By synergistically combining features of MSNs and
liposomes, the authors loaded a mixture of therapeutic (drugs, siRNA, and toxins) and
diagnostic agents (QDs) and modified this system to promote cell targeting, endosomal
escape, and nuclear accumulation of selected cargos.
Recently, Moon, Hyeon, and coworkers synthesized a monodisperse core–shell platform
consisting of a single iron oxide (IO) nanocrystal surrounded by a shell of mesoporous silica
(IO@MSNs).58 The size of these particles can easily be controlled below 100 nm. The
material was further functionalized with optical agents (FITC and rhodamine B) and PEG
chains. The OI capability of this material was used to determine its internalization in MCF-7
breast cancer cells. Moreover, the MR T2-weighted properties of IO@MSNs-PEG were
measured with a 1.5 T scanner. The r1 and r2 relaxivity values of the core–shell system were
3.40 and 245 mM−1 s−1, respectively. Fluorescent and T2-weighted phantom MR images
showed that the uptake of the particles is concentration dependent. To evaluate IO@MSNs-
PEG as a drug delivery vehicle, doxorubicin (DOX), a well-known anti-cancer agent, was
loaded, and the therapeutic efficacy of this system was determined using the SK-BR-3 cell
line. A cytotoxicity assay demonstrated the efficacy of this nanoparticle in delivering DOX
inside SK-BR-3 cells. The authors investigated the in vivo imaging abilities of this platform
in a breast cancer xenograft model. After 2 h post-injection, the accumulation of
nanoparticles in the tumor was detected by T2-weighted MR. The accumulation of
IO@MSNs-PEG was further confirmed by fluorescence imaging of the tumor and organs of
mice sacrificed 24 h after injection. Additionally, the authors recently reported the synthesis
of dye-doped IO-capped MSNs for multimodal imaging and drug delivery applications.59 In
this approach, the fluorophore (FITC or TRITC) was doped in the channels, and the IO
nanoparticles were chemically attached to the exterior surface of MSNs. Similar to the
previous study, the nanoparticles were further functionalized with PEG. The T2-weighted
MR properties of this material were characterized by a 1.5 T scanner. Interestingly, the
assembly of multiple IO nanoparticles on MSN resulted in a remarkable T2-weighted MR
contrast enhancement; r2 values for free IO and IO-MSN were 26.8 mM−1 s−1 and 76.2
mM−1 s−1, respectively. The multimodal imaging capabilities of this platform were tested in
vitro; fluorescence and T2-weighted MR images demonstrated that IO-MSN can be used as a
multimodal probe. DOX was loaded into the particles, and the antitumor efficacy of this
vehicle was tested using the B16-F10 melanoma cell line. In vivo evaluations were carried
out by intravenous injection into nude mice bearing tumors. At 3 h postinjection, the T2-
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weighted MR signal decreased at the tumor site, demonstrating passive targeting of IO-
MSNs by the enhanced permeability and retention (EPR) effect. The delivery of DOX to the
tumor tissue was demonstrated by fluorescence emitted by DOX accumulated at the tumor
site. The antitumor activity of this platform was evaluated using the TUNEL assay (Fig. 17).
Recently, Tamanoi and coworkers reported the synthesis of MSN-based theranostic particles
that contain an OI agent (FITC) and an anticancer therapeutic (camptothecin, CPT). In this
work, the authors focused on the toxicity, biodistribution, clearance, and therapeutic
properties of MSNs.60 The short- and long-term toxicities of MSNs were studied, and no
apparent toxicity in the animal model was observed. The biodistribution and excretion of
MSNs were determined by OI and ICP-OES, respectively. Fluorescent images showed that
MSN particles are mainly localized in the tumor, kidneys, and liver. Both renal and
hepatobiliary routes of excretion were investigated; the results obtained from the urine and
feces showed that the material is cleared through both pathways. To evaluate the therapeutic
efficacy of CPT-loaded MSNs in vivo, a xenograft model of MCF-7 human breast cancer
cells was used. The authors observed significant tumor growth inhibition with the
theranostic particles at the conclusion of the experiment.
Conclusions
Silica-based contrast agents are promising platforms for biomedical imaging and theranostic
applications. These materials can be engineered with numerous functionalities to achieve
specific physical and chemical properties. In vitro, the advantages of these platforms over
small molecule contrast agents have been demonstrated. In addition, recent in vivo results
have confirmed their promise as diagnostic tools. FDA approval of C dots for the first-in-
human clinical trial is an encouraging advance in this field. However, some areas still need
to be further investigated before translation into the clinic becomes a reality. These concerns
include the biocompatibility, long-term toxicity, targeting efficiency, and biodegradability of
silica-based nanoprobes. The present trend in this field is to develop theranostic platforms
that incorporate additional functionalities (i.e. therapeutic agents) with the in vivo imaging
modalities, rendering these platforms as theranostics. Interdisciplinary collaborations are
critically needed to enable the adoption of silica-based nanoprobes in the clinic as imaging
and therapeutic agents.
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Schematic showing the synthesis of SiNPs by the Stöber method (top), in which the
hydrolysis and condensation of TEOS is facilitated by the base in ethanol and water, and via
reverse phase microemulsion (bottom), in which TEOS is hydrolyzed at the micellar
interface and enters the aqueous droplet to form a silica nanoparticle. The scale bars
represent 1000 nm and 500 nm, respectively.
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Schematic representation of the synthesis of MCM-41 type MSN particles. The cationic
surfactant molecules self-assemble into hexagonal arrays in aqueous solution and the silica
precursors then hydrolyze and condense along the exterior of the micelles to form a
mesoporous material after extraction of the surfactant.
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Functionalization of MSNs by co-condensation (top) or the post-synthetic method (bottom).
A trialkoxysilane molecule bearing a functional group (green) is shown as an example of a
silica precursor. The structure-directing agent is represented by micelles (red).
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In vivo imaging of biodistribution of intravenously-injected surface-modified SiNPs at
different time points post-injection: (a) abdomen image and (b) back image. (A) OH–SiNPs,
(B) COOH–SiNPs. (C) PEG–SiNPs. Arrows indicate the location of the kidney (K), liver
(L), and urinary bladder (Ub). Reprinted from ref. 27 with permission from American
Chemical Society.
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Biodistribution analysis of C-dots in mice (top) and fluorescence pseudo-color imaging of a
mouse bladder ex vivo (bottom). (a, b) Percent of initial particle dose (% ID) retained for 6.0
nm (a) and 3.3 nm (b) diameter C dots. (c) Plot of retained particle concentration for 3.3 nm
(light gray) and 6.0 nm (black). (d) Plot of estimated particle excretion for 3.3 nm (light
gray) and 6.0 nm (black). (e–i) Pseudocolor images of Cy5 fluorescence in intact mouse
bladders showing the accumulation of 3.3 nm (e–h), followed by the negligible particle
fluorescence seen at 24 h postinjection (i). (j–m) Pseudocolor images of Cy5 fluorescence in
intact mouse bladders showing the accumulation of 6.0 nm (j–l) and at the 24 h end point
(m). (n) Pseudocolor image of a control mouse bladder. Reprinted from ref. 31 with
permission from American Chemical Society.
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Nodal mapping using multiscale NIR optical fluorescence imaging. (A) Whole-body
fluorescence imaging of the tumor site (T), draining inguinal (ILN) and axillary (ALN)
nodes, and communicating lymphatic channels (LCs). (B) Corresponding coregistered
white-light and high-resolution fluorescence images (top row) and fluorescence images only
(bottom row), revealing the nodal infrastructure of local and distant nodes, including high
endothelial venules (HEVs). (C) Whole-body fluorescence image of the tumor site 10
minutes after sub-dermal PEG-dot injection. (D) Delayed whole-body fluorescence image of
the tumor site 1 h after PEG-dot injection. (E) Percent increase in the area of fluorescence
(fluor) relative to that measured at 10 min post-injection for targeted and nontargeted
probes. Scale bars: 1.0 cm (A); 500 μm (B); 3 mm (C and D). Reprinted from ref. 32 with
permission from American Society for Clinical Investigation.
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Microscopic images of labeled monocyte cells: (a) optical image and (b) laser scanning
confocal fluorescence. (c, d) MR images of unlabeled (left) and labeled (right) monocyte
cells: (c) T1-weighted and (d) T2-weighted. (e) Flow cytometry results for the unlabeled
(red) and labeled (blue) monocyte cells indicating greater than 98% labeling efficiency
(inset shows the purity of the labeled cells; SS = side scatter, FS = forward scatter). (f) MTS
assay of the monocyte cells incubated with different amounts of nanoparticles. Reprinted
from ref. 35 with permission from John Wiley & Sons Inc.
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(Top) Control animals (without arthritis) that were intravenously-injected with two separate
doses of (A) saline, (B) 125 mg SiNPs per kg, or (C) 250 mg SiNPs per kg 12 h before
imaging. (Bottom) CIA animals with arthritis that were intravenously-injected with (D)
saline, (E) 125 mg SiNPs per kg, or (F) 250 mg per kg. Reprinted from ref. 36 with
permission from Clinical and Experimental Rheumatology.
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(A) Representative T1 and T2 relaxation maps of the hindlimbs of a mouse with early stage
CIA before and after SiNPs administration. (B) T2 relaxation maps of the hindlimbs of a
mouse with later stage CIA before and after receiving a SiNP-based contrast agent.
Reprinted from ref. 36 with permission from Clinical and Experimental Rheumatology.
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Schematic representation of the LbL self-assembly strategy for a dual optical and MR
imaging multimodal contrast agent. Reprinted from ref. 37 with permission from American
Chemical Society.
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(a) Dependence of per particle r1 and r2 values on the number of deposited Gd–DOTA
oligomer layers. (b) T1-weighted MR images of HT-29 cells that have been incubated with
various nanoparticles. From left to right: control cells without any nanoparticle, cells with
LbL particles, cells with LbL particles that have been noncovalently functionalized with
K7RGD, and cells with LbL particles that have been noncovalently functionalized with
K7GRD. Phase contrast optical (c, e, g, and i) and confocal microscopic images (d, f, h, and
j) of HT-29 cells that have been incubated with various nanoparticles: control cells without
any nanoparticle (c and d), cells with LbL particles (e and f), cells with LbL particles that
have been noncovalently functionalized with K7RGD (g and h), and cells with LbL particles
that have been noncovalently functionalized with K7GRD (i and j). Reprinted from ref. 37
with permission from American Chemical Society.
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Biodistribution of FITC–MSNs in an anesthetized rat before and after (90 min) intravenous
injection. The experimental conditions were set at 492 nm excitation and 518 nm emission
and (a) a longer shutter time (60 s) for visible imaging and (b) a 30 s shutter time. (c)
Biodistribution of ICG–MSNs in an anesthetized rat before and after intravenous injection
for 90 min. The ICG–MSNs sample showed less interference from autofluorescence in a
shorter shutter period (30 s). (d) ICG–MSNs in nude mice after intravenous injection for 3 h.
Reprinted from ref. 44 with permission from John Wiley & Sons Inc.
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(a) Precontrast and (b) postcontrast (2.1 μmol kg−1 dose) T1-weighted mouse MR image
showing aorta signal enhancement. (c) Precontrast and (d) postcontrast (31 μmol kg−1 dose)
mouse MR images showing liver signal loss due to T2-weighted enhancement. Reprinted
from ref. 46 with permission from American Chemical Society.
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Clinical 1.5 T MR images of a nude mouse 8 h (a) and 9 days (b) after implantation of Mag-
Dye@MSN-labeled hMSCs at the frontal cortex. (a) Using a clinical 1.5 T MR scanner, the
hMSCs revealed a dark dot at the frontal cortex (arrow). (b) Repeated MR scanning was
carried out 9 days after hMSC implantation. The stem cells could still be visualized as a
black dot at the frontal cortex. No migration of these cells is found (arrow head). Reprinted
from ref. 49 with permission from John Wiley & Sons Inc.
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(A) Images of the two subcutaneous injections of 100 mL MB-encapsulated SiNPs with
concentrations of 44 mg mL−1 (a) and 4.4 mg mL−1 (b). The acquisition was performed 2
min after injection. (B) Real-time in vivo abdomen imaging of an intravenous injection of
200 mL of MB-encapsulated SiNPs (44 mg mL−1) at different time points, post-injection.
Reprinted from ref. 53 with permission from Elsevier Ltd.
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Schematic illustration of the nanoporous particle-supported lipid bilayer, depicting the
disparate types of therapeutic and diagnostic agent that can be loaded within the nanoporous
silica core, as well as the ligands that can be displayed on the surface of the SLB. Reprinted
from ref. 57 with permission from Macmillan Publishers Ltd.
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TUNEL assay for apoptotic cell death. Tumor section from a mouse that was given
intravenous injection of (a) free IO-MSN, (b) DOX loaded IO-MSN (DOX 2 mg kg−1), and
(c) DOX loaded IO-MSN (DOX 4 mg kg−1). Arrows indicate examples of TUNEL-positive
(brown color) cells with apoptotic morphology. Reprinted from ref. 59 with permission from
American Chemical Society.
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